Abstract
Background : Colorectal cancer is a leading cause of tumor death, a consequence primarily of the spreading of malignant cells to liver and lung. Despite a range of interventions for liver metastases, the present knowledge of few specific molecular targets may contribute to late diagnosis and poorly effective therapy. Objective : To review the most innovative methodology employed to profile the signature(s) of metastatic colorectal cancer (mCRC) and to address diagnostic/therapeutic agents. Methods : A broad range Medline search was conducted, with particular attention to the search terms 'liver metastasis signature', in combination with 'targeting' and 'nanotechnology'. Results/conclusions : Studies aimed at the discovery of molecular signatures of cancers and metastasis are ongoing; the future of cancer/metastasis targeting is nanoparticle-mediated drug delivery.
| Original language | English |
|---|---|
| Pages (from-to) | 363-379 |
| Number of pages | 17 |
| Journal | Expert Opinion on Therapeutic Targets |
| Volume | 13 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2009 |
Fingerprint
Keywords
- Metastatic colorectal cancer
- Phage display
- Targeted therapy
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology
- Clinical Biochemistry
- Molecular Medicine
Cite this
Targeting the extracellular signature of metastatic colorectal cancers. / Marchi, Serena; Arap, Wadih; Pasqualini, Renata.
In: Expert Opinion on Therapeutic Targets, Vol. 13, No. 3, 03.2009, p. 363-379.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Targeting the extracellular signature of metastatic colorectal cancers
AU - Marchi, Serena
AU - Arap, Wadih
AU - Pasqualini, Renata
PY - 2009/3
Y1 - 2009/3
N2 - Background : Colorectal cancer is a leading cause of tumor death, a consequence primarily of the spreading of malignant cells to liver and lung. Despite a range of interventions for liver metastases, the present knowledge of few specific molecular targets may contribute to late diagnosis and poorly effective therapy. Objective : To review the most innovative methodology employed to profile the signature(s) of metastatic colorectal cancer (mCRC) and to address diagnostic/therapeutic agents. Methods : A broad range Medline search was conducted, with particular attention to the search terms 'liver metastasis signature', in combination with 'targeting' and 'nanotechnology'. Results/conclusions : Studies aimed at the discovery of molecular signatures of cancers and metastasis are ongoing; the future of cancer/metastasis targeting is nanoparticle-mediated drug delivery.
AB - Background : Colorectal cancer is a leading cause of tumor death, a consequence primarily of the spreading of malignant cells to liver and lung. Despite a range of interventions for liver metastases, the present knowledge of few specific molecular targets may contribute to late diagnosis and poorly effective therapy. Objective : To review the most innovative methodology employed to profile the signature(s) of metastatic colorectal cancer (mCRC) and to address diagnostic/therapeutic agents. Methods : A broad range Medline search was conducted, with particular attention to the search terms 'liver metastasis signature', in combination with 'targeting' and 'nanotechnology'. Results/conclusions : Studies aimed at the discovery of molecular signatures of cancers and metastasis are ongoing; the future of cancer/metastasis targeting is nanoparticle-mediated drug delivery.
KW - Metastatic colorectal cancer
KW - Phage display
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=65549142182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65549142182&partnerID=8YFLogxK
U2 - 10.1517/14728220902762910
DO - 10.1517/14728220902762910
M3 - Article
C2 - 19236157
AN - SCOPUS:65549142182
VL - 13
SP - 363
EP - 379
JO - Expert Opinion on Therapeutic Targets
JF - Expert Opinion on Therapeutic Targets
SN - 1472-8222
IS - 3
ER -